As the biopharma industry and individual biotech companies themselves mature, partnering options are also expanding. At the early stages of the drug development life cycle, companies now have options outside of the historical biotech-pharma pair-up.
What other partnership options do biotech companies use today, from translation of academic research to industry and co-development? How do biotech companies identify the right ecosystem and partners? What are the partnering and transaction strategies of small companies in a competitive environment? Are some therapeutic areas more likely to lead to inter-biotech collaborations?
Moderator: Kathrin Ballesteros, Venture Partner, NLC – The European Healthtech Venture Builder 
